Family History of Gastric Cancer and Helicobacter pylori Treatment
To the Editor: In the trial reported by Choi et al. (Jan. 30 issue), 1 participants with Helicobacter pylori infection were assigned to receive eradication treatment or placebo. Patients in the treatment group received clarithromycin-containing triple therapy twice a day for 7 days. At the end of th...
Gespeichert in:
Veröffentlicht in: | The New England journal of medicine 2020-05, Vol.382 (22), p.2170-2172 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | To the Editor:
In the trial reported by Choi et al. (Jan. 30 issue),
1
participants with
Helicobacter pylori
infection were assigned to receive eradication treatment or placebo. Patients in the treatment group received clarithromycin-containing triple therapy twice a day for 7 days. At the end of the trial, patients in either group who were still infected with
H. pylori
were treated with bismuth-based quadruple therapy for 10 days.
1
It is important to note that the American College of Gastroenterology guidelines for
H. pylori
treatment underwent updates during the time the trial was being conducted.
2-4
Clarithromycin-based triple therapy is no longer . . . |
---|---|
ISSN: | 0028-4793 1533-4406 |
DOI: | 10.1056/NEJMc2003542 |